JPRN-UMIN000005922
已完成
未知
Phase 1 clinical study of multiple intravenous doses of TRM-1106 in healthy Japanese adult men - TRM-1106 multiple doses study
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Healthy male subjects
- 发起方
- Terumo Corporation
- 入组人数
- 20
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •1\) Subject who has been tested positive in a urine drug test or has a history of drug abuse. 2\) Subject who has been tested positive for HBs antigen, HCV antibody or HIV antibody, or who has a positive serological test for syphilis. 3\) Subject who has a history of hypersensitivity or allergy to the study drug (active component and additives) 4\) Subject who currently has or has a history of peptic ulcer; or subject who currently has or has a history of asthma. 5\) Subject with clinically significant disease related to the heart, liver, kidneys, respiratory system, gastrointestinal system, endocrine system, immune system, skin, blood, or psychiatric/nervous system. 6\) Subject who has liver function test values (T\-Bil/D\-Bil, ALT (GPT), AST (GOT), gamma\-GTP and ALP) that exceed the facility's upper limit. However, if the investigator deems that the reason for exceeding the limit is not due to the liver, the subject may be enrolled. 7\) Subject who currently has or have a history of clinically significant bleeding or bleeding tendency. 8\) Subject who has taken other medication or supplements within 1 week prior to study drug administration. 9\) Subject who need to take other medication concurrently while participating in this study. 10\) Subject who smoked tobacco within 1 month prior to study drug administration. 11\) Subject who habitually consume a large amount of alcohol (ingestion of \>\=60 g per day as pure alcohol), or have ingested alcohol within 3 days prior to study drug administration. 12\) Subject who has ingested food products containing St. John's wort within 2 weeks prior to study drug administration. 13\) Subjects who has ingested grapefruit or processed grapefruit products within 1 week prior to study drug administration.
结局指标
主要结局
未指定
相似试验
招募中
1 期
A Phase-I clinical study of intravenous AntiPlatelet, AntiCoagulant (APAC) in healthy subjects.CTRI/2023/04/051500Cadila Pharmaceutical Limited
尚未招募
1 期
Mesenchymal Stem Cell Therapy For Covid 19Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/08/027043eurogen Brain and Spine Institute
已完成
1 期
Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal disseminatioGastric cancer with peritoneal disseminationJPRN-UMIN000018658The Jikei University School of Medicine18
已完成
不适用
A prospective and multicenter trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosisJPRN-UMIN000013559Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine10
已完成
不适用
Phase1 clinical study of a single intravenous dose of TRM-1106 in healthy Japanese adult meJPRN-UMIN000005914Terumo Corporation30